Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.

In English

Författare

Summary, in English

We used a recombinant lentiviral vector (rLV) for gene delivery of GDNF to the striatum, and assessed its neuroprotective effects in the intrastriatal 6-hydroxydopamine (6-OHDA) lesion model.The level of GDNF expression obtained with the rLV-GDNF vector was dose-related and ranged between 0.9-9.3 ng/mg tissue in the transduced striatum, as determined by ELISA, and 0.2-3.0 ng/mg tissue were detected in the ipsilateral substantia nigra (SN), due to anterograde transport of the GDNF protein. GDNF expression was apparent at 4 days and maintained for > 8 months after injection. Striatal delivery of rLV-GDNF efficiently protected the nigral dopamine (DA) neurons and their projection, against the 6-OHDA lesion (65-77% of intact side). Sprouting of the lesioned axons was observed along the nigrostriatal pathway, precisely corresponding to the areas containing anterogradely transported GDNF.

Avdelning/ar

Publiceringsår

2002

Språk

Engelska

Sidor

75-82

Publikation/Tidskrift/Serie

NeuroReport

Volym

13

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

Lippincott Williams & Wilkins

Ämne

  • Neurosciences

Nyckelord

  • Lentivirus : genetics
  • Luminescent Proteins : pharmacokinetics
  • Motor Activity : drug effects
  • Nerve Tissue Proteins : genetics
  • Nerve Tissue Proteins : pharmacokinetics
  • Nerve Tissue Proteins : therapeutic use
  • Neurons : drug effects
  • Neurons : metabolism
  • Neuroprotective Agents : therapeutic use
  • Oxidopamine : pharmacology
  • Parkinson Disease : pathology
  • Parkinson Disease : physiopathology
  • Parkinson Disease : therapy
  • Rats
  • Sprague-Dawley
  • Substantia Nigra : drug effects
  • Substantia Nigra : pathology
  • Support
  • Non-U.S. Gov't
  • Tyrosine 3-Monooxygenase : metabolism
  • Indicators and Reagents : pharmacokinetics
  • Genetic Vectors
  • Gene Transfer Techniques
  • Female
  • Dopamine : metabolism
  • Corpus Striatum : pathology
  • Corpus Striatum : drug effects
  • Animal

Status

Published

Forskningsgrupp

  • Neurobiology

ISBN/ISSN/Övrigt

  • ISSN: 1473-558X